Navigation Links
Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO
Date:6/3/2010

Hackensack, NJ, June 03, 2010 The John Theurer Cancer Center at Hackensack University Medical Center announced today that its physicians and researchers will present 16 abstracts on treatment and diagnostic progress in many different areas of oncology during the Annual Meeting of American Society of Clinical Oncology (ASCO) in Chicago, IL from June 4-8.

"At the John Theurer Cancer Center, we're dedicated to providing extraordinary cancer care to our patients, which includes conducting high-quality cancer research and cutting-edge clinical trials," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chairman and Executive Administrative Director, the John Theurer Cancer Center. "We're pleased to add to an important body of research at this premier oncology conference."

Abstracts from the John Theurer Cancer Center research that are scheduled to be presented include:

  • Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM). (8031) (Poster Discussion Session) - Friday, June 4 from 2:00 p.m. - 6:00 p.m. in E450a

  • Phase II study of denileukindiftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial. (8045) (Poster Discussion Session) - Friday, June 4 from 2:00 p.m. - 6:00 p.m. in E450a

  • Response of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with nongerminal center B-cell phenotype to lenalidomide (L) alone or in combination with rituximab (R). (8038) (Poster Discussion Session) - Friday, June 4 from 2:00 p.m. - 6:00 p.m. in E450a

  • The association between the Mantle Cell Lymphoma International Prognostic Index (MIPI) and survival in patients treated with rituximab-HCVAD (RHCVAD) alternating with rituximab-methotrexate-AraC (R-MTX-AraC). (8092) (General Poster Session) Saturday, June 5 from 8:00 am 12:00 p.m. in S Hall A2

  • Effect of front-line therapy with either high-dose therapy and autologous stem cell rescue (HDT/ASCR) or dose-intensive therapy (R-Hypercvad) on outcome in mantle cell lymphoma (MCL). (8067) (General Poster Session) Saturday, June 5 from 8:00 am 12:00 p.m. in S Hall A2

  • Impact of high-risk classification by FISH on overall survival in myeloma: An Eastern Cooperative Oncology Group (ECOG) study E4A03. (10546) (General Poster Session) Saturday, June 5 from 8:00 am 12:00 p.m. in S Hall A2

  • Interim results of phase II trial of pegylated liposomal doxorubicin (PLD) followed by bexarotene in advanced cutaneous T-cell lymphoma (CTCL). (8053) (General Poster Session) Saturday, June 5 from 8:00 am 12:00 p.m. in S Hall A2

  • Neurotoxic and peripheral neuropathic effects in preclinical and clinical studies of carfilzomib (CFZ), a novel proteasome inhibitor (PI). (8135) (General Poster Session) Saturday, June 5 from 8:00 am 12:00 p.m. in S Hall A2

  • Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) for patients with relapsed indolent B-cell lymphoma (RIL). (8078) (General Poster Session) Saturday, June 5 from 8:00 am 12:00 p.m. in S Hall A2

  • Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study. (8125) (General Poster Session) Saturday, June 5 from 8:00 am 12:00 p.m. in S Hall A2

  • Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM). (8133) (General Poster Session) Saturday, June 5 from 8:00 am 12:00 p.m. in S Hall A2

  • Effect of early chemotherapy intensification with BEACOPP in high-risk, interim-PET positive, advanced-stage Hodgkin lymphoma on overall treatment outcome of ABVD. (8006) (Oral Abstract Session) - Saturday, June 5 from 1:00 p.m. 4:00 p.m. in E354a

  • Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study. (8003) (Clinical Science Symposium) Saturday, June 5 from 4:30 p.m. 6:00 p.m. in E354a

  • Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM). (8001) (Clinical Science Symposium) Saturday, June 5 from 4:30 p.m. 6:00 p.m. in E354a

  • Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM). (8000) (Clinical Science Symposium) Saturday, June 5 from 4:30 p.m. 6:00 p.m. in E354a


'/>"/>

Contact: Amy Leahing
amy.leahing@widmeyer.com
646-213-7245
John Theurer Cancer Center
Source:Eurekalert

Related medicine news :

1. Strauss Radio Strategies - The Nation's Leading Radio Media Relations Firm - Expands Government Business with Award on GSA Schedule
2. Intellicig Clinches Exclusive Deal with Retail Distribution-Giant to Distribute Their Industry Leading Electronic Cigarettes
3. Medco Acquires Leading Genetics Healthcare Company, DNA Direct
4. Leading Sales and Operations Planning (S&OP) Provider Steelwedge Announces i2 Exchange Program
5. Mental illnesses are second leading cause of time off work in Spain
6. The International Association of Pediatricians & Leading Physicians of the World Helps New Mothers Find Top Pediatricians in Their Area
7. Two of Cincinnatis Leading Employee Benefit Providers Merge to Offer Clients Greater Expertise and Service
8. NeuroFocus Adds Two More of the Worlds Leading Neuroscientists to its Advisory Board
9. Sushi & Breastfeeding Join Birth Defects & Preterm Birth as Leading Concerns of Moms
10. Leading COPD Drug Wont Harm Heart: FDA
11. MPE Inc., a Leading Supplier of Recycled Protective Garments, Becomes Approved Vendor on DOD EMALL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
Breaking Medicine Technology: